Project Grant R01HL186881
Award Date 8/10/26
Completion Date 5/31/31
Dollars Obligated $813K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Regents of the University of California, San Francisco a $3.26 million Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) for a four-year period beginning September 1, 2025. This research initiative investigates immune activation and region-specific myocardial arrhythmic substrate in sudden cardiac death (SCD) victims with HIV. The study builds upon the investigators'...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services, awarded $795,464 to The Regents of the University of California, San Francisco on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into adaptive-like natural killer cells in pulmonary cytomegalovirus reactivation. The project investigates whether local cytomegalovirus-specific natural killer cell immune responses in the lungs potentiate...
- The National Heart, Lung, and Blood Institute awarded $1.555 million to the University of Maryland, Baltimore on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to model and treat chronic HIV-induced lung infections. The research investigates immune mechanisms underlying increased susceptibility to respiratory infections in people living with HIV. The project focuses on how chronic HIV infection impairs dendritic cell differentiation and function, hypothesizing...
- The National Heart, Lung, and Blood Institute awarded Northern California Institute For Research And Education, Inc. (NCIRE) $3.002 million on August 7, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a prospective longitudinal study of cardiac fibro-inflammation progression in women with HIV. The research repeats cardiac magnetic resonance imaging in returning participants approximately eight years after their initial scans, drawing from the MACS-WIHS...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $874,531 on May 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to model dynamic CD8+ T cell–virus interactions in post-treatment control of HIV. The project comprehensively defines mechanistic features of CD8+ T cell responses that most strongly relate to control of HIV after stopping antiretroviral therapy. Research will examine...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $1,097,760 on February 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund a Project Grant (R35HL183538) investigating mechanisms of age-related pulmonary fibrosis and lung regeneration. The research program addresses idiopathic pulmonary fibrosis (IPF), a progressive disease affecting approximately 200,000 patients annually in the United States with...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $200,880 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop integrated host-microbe metagenomic sequencing methods for diagnosing and predicting complications in lung transplant recipients. The project will develop metagenomic classifiers from bronchoalveolar lavage fluid to more accurately diagnose lower respiratory tract infection in...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2.98 million Project Grant (CFDA 93.837 – Cardiovascular Diseases Research) to the University of California, San Francisco to conduct a four-year research study examining the impact of asymptomatic cytomegalovirus (CMV) infection on cardiovascular event risk in people with HIV (PWH). The primary deliverable is a large-scale Mendelian randomization study that will assess whether CMV-associated plasma proteomic signatures and...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded the J. David Gladstone Institutes $1,569,656 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate chromatin regulation of immune cells in myocardial inflammation, with performance through May 31, 2030. The project elucidates BRD4-mediated chromatin and gene regulatory networks controlling monocyte differentiation and macrophage function during myocardial infarction, with the goal of...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $363,556 on February 23, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct secondary cross-sectional analyses examining the association between body composition and patient-centered outcomes in advanced interstitial lung disease. The funded research will analyze data from two prospective cohort studies to define how obesity and...